SCHEMBL5924414

SCHEMBL5924414

CCCCCCCCNC(=O)c1ccc(O)c(N)c1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
NAAA Q02083 4/20 0.58
SMN1; SMN2 Q16637 2/20 0.55
MLYCD O95822 1/20 0.55
THRA P10827 1/20 0.51
THRB P10828 1/20 0.51
MEN1 O00255 1/20 0.50
ALDH1A1 P00352 1/20 0.50
MAPT P10636 1/20 0.50
KMT2A Q03164 1/20 0.50
TRPV1 Q8NER1 1/20 0.50
SMPD1 P17405 1/20 0.48
FOLH1 Q04609 2/20 0.47
APP P05067 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5270854 1.00 CA2 (0.60) CA2L3MBTL1NAAASMN1; SMN2MLYCD
SCHEMBL28051808 0.94 SMN1; SMN2 (0.62) CA2L3MBTL1NAAASMN1; SMN2MLYCD
SCHEMBL5924238 0.89 CA2 (0.60) CA2L3MBTL1NAAASMN1; SMN2MLYCD
SCHEMBL5924457 0.89 CA2 (0.60) CA2L3MBTL1NAAASMN1; SMN2MLYCD
SCHEMBL5924372 0.89 CA2 (0.60) CA2L3MBTL1NAAASMN1; SMN2MLYCD
SCHEMBL5924377 0.89 CA2 (0.60) CA2L3MBTL1NAAASMN1; SMN2MLYCD
SCHEMBL5924141 0.89 CA2 (0.60) CA2L3MBTL1NAAASMN1; SMN2MLYCD
SCHEMBL2955335 0.88 L3MBTL1 (0.63) CA2L3MBTL1NAAASMN1; SMN2MLYCD
SCHEMBL2952982 0.88 L3MBTL1 (0.63) CA2L3MBTL1NAAASMN1; SMN2MLYCD
SCHEMBL2954407 0.88 L3MBTL1 (0.63) CA2L3MBTL1NAAASMN1; SMN2MLYCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060089316-A1 Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof BROWN TRUMAN R 2006-04-27 US disclosed
US-5514676-A TO INHIBIT THE FORMATION OF ADVANCED GLYCOSLYATION PRODUCTS BY THE NONENZYMATIC CROSSLINKING OF PROTEINS WITH REDUCING SUGARS, USED IN FOOD PRESERVATION AND TO PREVENT PROTEIN AGING IN COLLAGEN OR LENSES IN THE EYE PRESERVATION THE ROCKEFELLER UNIVERSITY (US) 1996-05-07 US disclosed
US-5476849-A Inhibiting advanced glycosylation and/or crosslinking of target protein THE ROCKEFELLER UNIVERSITY (US) 1995-12-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089316-A1 Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof ALDOA, FBP1, GYS2 CA2 3458/4885L3MBTL1 575/4885NAAA 4068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.